Sign up for news & promotions:
MYC Primary Antibody
|Aliases||MRTL; MYCC; c-Myc; bHLHe39|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Synthesized peptide of human MYC (AA: 23-37)|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||Western Blot.|
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2:Flow cytometric analysis of Hela cells using MYC mouse mAb (green) and negative control (red).
This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini.
|References (references)||1.J Exp Clin Cancer Res. 2018 Sep 27;37(1):239. 2.Am J Surg Pathol. 2018 Nov;42(11):1488-1494.|